Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

Ítems similars

• Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
  per: Brusasco, V, et al.
  Publicat: (2003)
• Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
  per: Hodder, Richard, et al.
  Publicat: (2007)
• The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study)
  per: Beeh, Kai-Michael, et al.
  Publicat: (2016)
• Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
  per: Buhl, Roland, et al.
  Publicat: (2015)
• Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations
  per: Beeh, Kai-Michael, et al.
  Publicat: (2009)